Controversies over interferon in the adjuvant treatment of melanoma;Controversias sobre el interferón en el tratamiento adyuvante del melanoma

Actas Dermo-Sifiliograficas

Volumn 95, Issue 10, 2004, Pages 597-605

  Botella Estrada, Rafael ^a  

^a INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

Author keywords

Adjuvant treatment; Interferon; Melanoma

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; CANCER VACCINE; CISPLATIN; DACARBAZINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERFERON; INTERLEUKIN 2; MELANOMA VACCINE; VINBLASTINE;

ADULT; ALGORITHM; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL PROTOCOL; CONTROLLED STUDY; HUMAN; LIVER TOXICITY; LYMPH NODE BIOPSY; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MELANOMA; NEUROTOXICITY; REVIEW; SENTINEL LYMPH NODE; SKIN CANCER;

EID: 13444278907     PISSN: 00017310     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0001-7310(04)76894-5     Document Type: Review

References (34)

1. Brown CK, Kirkwood JM. Adjuvant therapy for melanoma. En: Sober AJ, Haluska FG, editors. Skin Cancer. Hamilton, BC Decker Inc, 2001; p. 206-224.
2. McKenna RM, Oberg KE. Antibodies to interferon-alpha in treated cancer patients: Incidence and significance. J Interferon Cytokine Res 1997;17:141-3.
3. Kirkwood JM. Melanoma. En: De Vita Jr. VT, Hellman S, Rosenberg SA, editors. Biologic therapy of cancer: Principles and practice. Philadelphia: JB Lippincott, 1995:388-411.
4. Frank SJ, Meyers M. Interferon as adjuvant therapy for high risk melanoma. Melanoma Lett 1995;13:1-4.
5. Hakansson A, Gustafsson B, Krysander L, Hakansson L. Effect of IFN-alfa on tumor-infiltrating mononuclear cells and regressive changes in metastatic malignant melanoma. J Interferon Cytokine Res 1998;18:33-9.
6. Slaton JW, Perrotte F, Inoue K, Dinney CP, Fidler IJ. Interpheron-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimisation of biological dose and schedule. Clin Cancer Res 1999;5:2726-34.
7. Legha SS. Current therapy for malignant melanoma. Semin Oncol 1989;16(Suppl 1):34-44.
8. Steiner A, Wolf C, Pehamberger H. Comparison of the effects of three different treatment regimens of recombinant interferons (r-IFN-alpha, r-IFN-gamma, and r-IFN-alpha plus cimetidine) in disseminated malignant melanoma. J Cancer Res Clin Oncol 1987;113:459-65.
9. Sharfman WH. The role of adjuvant interferon in high risk melanoma patients. Dermatol Surg 2000;26:607-8.
10. Cascinelli N, Bufalino R, Morabito A, Mackie R. Results of adjuvant interferon study in WHO melanoma programme. Lancet 1994;343:913-4.
11. Cascinelli N, Belli F, MacKie RM, Santinami M, Bufalino R, Morabito A. Effect of long-term adjuvant therapy with interpheron alpha-2a in patients with regional node metastases from cutaneous melanoma: A randomised trial. Lancet 2001;358:866-9.
12. Grob JJ, Dreno B, De la Salmoniere P, et al. Randomised trial of interferon α-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. Lancet 1998;351:1905-10.
13. Pehamberger H, Soyer HP, Steiner A, et al. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. J Clin Oncol 1998;16:1425-9.
14. Cameron DA, Cornbleet MC, Mackie RM, et al. Adjuvant interpheron alpha 2b in high risk malignant melanoma. The Scottish study. Br J Cancer 2001;84:1146-9.
15. Hancock BW, Wheatley K, Harris S, et al. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study-United Kigdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon alfa-2a in high-risk resected malignant melanoma. J Clin Oncol 2004;22:1-9.
16. Lens MB, Dawes M. Interferon alfa therapy for malignant melanoma: A systematic review of randomized controlled trials. J Clin Oncol 2002;20:1818-25.
17. Creagan ET, Dalton RJ, Ahmann DL, et al. Randomized surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. J Clin Oncol 1995;13:2776-83.
18. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Adjuvant therapy for high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996;14:7-17.
19. Kirkwood JM, Ibrahim JG, Sondak VK, et al. High- and low-dose interferon alfa-2b in high-risk melanoma: First analysis of Intergroup trial E1690/S9111/C9190. J Clin Oncol 2000;18:2444-58.
20. Kirkwood JM, Ibrahim JG, Sosman JA, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survivall compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001;19:2370-80.
21. Livingston PO, Wong GY, Adluri S, et al. Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 1994;12:1036-44.
22. Moschos SJ, Kirkwood JM, Konstantinopoulos PA. Present status and future prospects for adjuvant therapy of melanoma: Time to build upon the foundation of high-dose interferon alfa-2b. J Clin Oncol 2004;22:11-4.
23. Kirkwood JM, Manola J, Ibrahim J, Sondak V, Ernstoff MS, Rao U. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 2004;10:1670-7.
24. Ready N, Weinstock MA. Adjuvant high-dose interferon therapy for high-risk melanoma. Arch Dermatol 2003;139: 1635-7.
25. Eggermont AMM, Suciu S, Ruka W, Lienard D. Analysis of the EORTC Melanoma Group 18952 randomized trial on 2 intermediate dose schedules of IFN-alpha2b compared with observation in 1388 patients with high risk melanoma stages IIB-III. ECCO 12- the European Cancer Conference Copenhagen, Denmark-Vol. 1, N° 5, Sept. 21-25, 2003, Abstr., N°. 1067.
26. Ross MI (personal communication). Sentinel node based surgical melanoma trials: Sunbelt Melanoma Trial. Perspectives in melanoma management. Amsterdam 10-11; Octubre 2003.
27. Schuchter LM. Adjuvant interferon therapy for melanoma: high-dose, low-dose, no dose, which dose? J Clin Oncol 2004;22:7-10.
28. Perrott RE, Glass LF, Reinigen DS, Fenske NA. Reassessing the role of lymphatic mapping and sentinel lymphadenectomy in the management of cutaneous malignant melanoma. J Am Acad Dermatol 2003;49:567-88.
29. th Ann Mtg Am Soc Clin Oncol, ASCO, Chicago, IL, USA, May 31-June 3, 2003, vol 22, May 2003, Abstr 2912.
30. Eggermont AMM. The role of interferon-alpha in malignant melanoma remains to be defined. Eur J Cancer 2001; 37:2147-53.
31. Spider LE, Grossbard ML, Ernstoff MS, et al. Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor. J Clin Oncol 2000;18:1614-21.
32. Spider LE. GM-CSF shows promise in prolonging high-risk melanoma survival. Dermatology Times 2004;25:52.
33. Lawson D, Kirkwood JM. Granulocyte-macrophage colony-stimulating factor: Another cytokine with adjuvant therapeutic benefit in melanoma? J Clin Oncol 2000;18: 1603-5.
34. Hauschild A, Weichenthal M, Balda BR, et al. Prospective randomized trial of interferon alfa-2b and interleukin-2 as adjuvant treatment for resected intermediate- and high-risk primary melanoma without clinically detectable node metastasis. J Clin Oncol 2003;21:2883-8.